Cargando…

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards opti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hacker, Ulrich T., Bentler, Martin, Kaniowska, Dorota, Morgan, Michael, Büning, Hildegard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409174/ https://www.ncbi.nlm.nih.gov/pubmed/32674264 http://dx.doi.org/10.3390/cancers12071889

Ejemplares similares

Modifying immune responses to adeno-associated virus vectors by capsid engineering
por: Bentler, Martin, et al.
Publicado: (2023)

Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors
por: Meumann, Nadja, et al.
Publicado: (2022)

Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity
por: Mingozzi, Federico, et al.
Publicado: (2015)

Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
por: Büning, Hildegard, et al.
Publicado: (2019)

Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives
por: Prakoso, Darnel, et al.
Publicado: (2021)

Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
por: Bartel, Melissa, et al.
Publicado: (2011)

Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity
por: Rossi, Axel, et al.
Publicado: (2019)

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
por: Naso, Michael F., et al.
Publicado: (2017)

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Ronzitti, Giuseppe, et al.
Publicado: (2020)

Autophagy determines efficiency of liver‐directed gene therapy with adeno‐associated viral vectors
por: Hösel, Marianna, et al.
Publicado: (2017)

Adeno-associated virus type 2 (AAV2) uncoating is a stepwise process and is linked to structural reorganization of the nucleolus
por: Sutter, Sereina O., et al.
Publicado: (2022)

DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
por: Schnödt, Maria, et al.
Publicado: (2016)

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
por: Arjomandnejad, Motahareh, et al.
Publicado: (2023)

Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014)

Molecular design for recombinant adeno-associated virus (rAAV) vector production
por: Aponte-Ubillus, Juan Jose, et al.
Publicado: (2017)

GluA4-Targeted AAV Vectors Deliver Genes Selectively to Interneurons while Relying on the AAV Receptor for Entry
por: Hartmann, Jessica, et al.
Publicado: (2019)

Methylation Status of the Adeno-Associated Virus Type 2 (AAV2)
por: Tóth, Renáta, et al.
Publicado: (2019)

Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy
por: Sen, Dwaipayan, et al.
Publicado: (2013)

Rapid characterization of adeno-associated virus (AAV) gene therapy vectors by mass photometry
por: Wu, Di, et al.
Publicado: (2022)

Gene therapy of adeno‐associated virus (AAV) vectors in preclinical models of ischemic stroke
por: Wang, Jing, et al.
Publicado: (2023)

Improved targeting of human CD4(+) T cells by nanobody-modified AAV2 gene therapy vectors
por: Hamann, Martin V., et al.
Publicado: (2021)

Optimization of the Capsid of Recombinant Adeno-Associated Virus 2 (AAV2) Vectors: The Final Threshold?
por: Aslanidi, George V., et al.
Publicado: (2013)

 Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes
por: McClements, Michelle E., et al.
Publicado: (2017)

Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
por: Gehrke, Miranda, et al.
Publicado: (2022)

Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
por: Ahmadi, Elham, et al.
Publicado: (2021)

Adeno-Associated Virus (AAV) Versus Immune Response
por: Rabinowitz, Joseph, et al.
Publicado: (2019)

Adeno-associated Virus (AAV) Serotypes Have Distinctive Interactions with Domains of the Cellular AAV Receptor
por: Pillay, Sirika, et al.
Publicado: (2017)

Rational Design of Gene Therapy Vectors
por: Pan, Dao, et al.
Publicado: (2019)

Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse
por: Schuster, Daniel J., et al.
Publicado: (2014)

Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy
por: Hagen, Sven, et al.
Publicado: (2014)

Adeno‐associated virus (AAV)-based gene therapy for glioblastoma
por: Xu, Xin, et al.
Publicado: (2021)

Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
por: Buck, Thilo M., et al.
Publicado: (2020)

Deciphering the role of tau in neurodegeneration using Adeno-Associated Viral (AAV) vectors to express human tau in the mouse forebrain
por: Lathuilière, Aurélien, et al.
Publicado: (2013)

Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno‐Associated Viral Vector rAAV9P1
por: Bauer, Amelie, et al.
Publicado: (2022)

Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood
por: Smith, Corinne J., et al.
Publicado: (2022)

Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters
por: Nieuwenhuis, Bart, et al.
Publicado: (2023)

Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses
por: Scarpitta, Allan, et al.
Publicado: (2021)

Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line
por: Stiefelhagen, Marius, et al.
Publicado: (2008)

The recombinant adeno-associated virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammerhead ribozyme: a self-complementary AAV2 vector improves the gene expression
por: Zhong, Shumei, et al.
Publicado: (2004)

Adeno-Associated Virus Receptor-Binding: Flexible Domains and Alternative Conformations through Cryo-Electron Tomography of Adeno-Associated Virus 2 (AAV2) and AAV5 Complexes
por: Hu, Guiqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uo62n3f2v493k06vja2sts3kie